VPA10980/042/001

Pergosafe 0.5 mg film-coated tablets for horses

Variation	Summary	Date
Vet - G.I.2 z)	VRA-R - Vet - G.I.2 z) - - Vet - G.I.2 z) - Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of a generic/hybrid medicinal product following assessment of the same change for the reference product - Other changes under this code level, e.g. variations outlined in section 6 and 7 of this guidance	09/03/26
Vet - F.II.f.1 a) 1.	VRA-R - Vet - F.II.f.1 a) 1. - - Vet - F.II.f.1 a) 1. - Change in the shelf-life or storage conditions of the finished product - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)	23/02/26
Vet - A2	VNRA - Vet - A2 - Change in the (invented) name of the veterinary medicinal product - A2 Administratvie changes: Change in the (invented) name of the veterinary medicinal product	03/03/25
Vet - C1	VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV)	09/01/25
Vet - C6	VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17	09/01/25
Vet - F.I.a.1 a)	VRA-S - Vet - F.I.a.1 a) - a) Introduction of a manufacturer of the active substance supported by an ASMF - F.I.a.1 a) - Quality Changes - Active Substance - Manufacture - Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - Introduction of a manufacturer of the active substance supported by an ASMF	19/07/24